Goal: The effect of pulse pressure and interactions with type of antihypertensive therapy on mortality after acute ischemic stroke has not been previously evaluated. Materials and Methods: A retrospective cohort study was conducted to evaluate the independent and interactive effects of pulse pressure and antihypertensive class (specifically angiotensin converting enzyme inhibitor/angiotensin type 1 receptor blocker, or beta blocker) on mortality following acute ischemic stroke. Findings/Conclusions: 343 patients were identified with 49 months of follow-up. Baseline pulse pressure was 64 mmHg and age was 66.5 years. Patients were divided at a pulse pressure of 70. Patients with pulse pressure ≥ 70 were older (p < 0.001) and had higher comorbid vascular burden (p = 0.031) than those with pulse pressure < 70. Pulse pressure did not remain a significant predictor of follow-up mortality after adjustment for baseline comorbidities. Angiotensin converting enzyme inhibitor/angiotensin type 1 receptor blocker based therapy was associated with lower follow-up mortality when beta blocker was not used in pulse pressure < 70 group (odds ratio 0.07, 95% confidence interval 0.01 -0.48). Prospective analysis will be needed to confirm the protective effect of angiotensin converting enzyme inhibitor/angiotensin type 1 receptor blocker based on pulse pressure in acute ischemic stroke.
Introduction
The relationship between blood pressure (BP) control and short and long term outcomes in patients with acute ischemic stroke (AIS) is highly complex and not well understood with conflicting data. More than half of ischemic stroke patients had systolic blood pressure (SBP) above 160 mmHg within the first 48 hours of symptom onset in the International Stroke Trial (IST) [1] . However, the IST evaluation demonstrated a U-shaped relationship between SBP at both 14-day and 6 month outcomes. The most interesting was an increased risk of death at 14 days by 17.9% for every 10 mmHg SBP less than 150 mmHg compared to a 3.8% increased risk of death with each 10 mmHg increase above 150 mmHg (3.6% vs.
1.1% for 6 month death or dependency) [1] . On the other hand, recurrent AIS within 14-days was directly associated with increased SBP, which independently predicted the likelihood of AIS in a multivariate analysis [1] .
Currently, the evidence does not support aggressive management of BP during AIS as a global strategy [2] . Although significantly elevated BP in AIS is deleterious, rapid reduction of SBP has been associated with a higher mortality [3] with cerebral hypoperfusion and increased cardiac events [4] . Reducing diastolic BP (DBP) by >20% also significantly increases the risk of death [5] . Citing conflicting evidence, the 2013 ACC/AHA Guidelines for the "Early Management of Patients with Acute Ischemic Stroke" did not specify BP targets and suggest using "best clinical judgment" and "to initially lower the SBP by 15% and monitor for neurological deterioration related to the (blood) pressure lowering" [2] .
An important component of BP is the difference between SBP and DBP, or the pulse pressure (PP) [6] . Increased PP above a population norm has been associated with inferior outcomes in AIS [7] [8] [9] [10] [11] , especially when PP exceeds 70 mmHg [7] . With the varying components of BP and the diversity of findings among the clinical trials of BP in AIS, the optimal approach to BP management in AIS remains unclear. Likewise, the choice of antihypertensive treatment in AIS and during follow-up has not been well established [12] . Angiotensin converting enzyme inhibitors (ACEI) were demonstrated to prevent recurrent strokes [13] and improve hospital [14] and follow-up survival [15] . Some studies suggested benefit with angiotensin II receptor blocker (ARB) [16] [17] [18] [19]; while calcium channel blocker (CCB) [5] [20] and beta-adrenergic blocker (BB) [21] [22] [23] therapies failed to show consistent reduction in mortality and prevention of recurrent stroke.
The effects of anti-hypertensive therapy on outcomes in patients with AIS and widened pulse pressure (WPP) have not been well studied previously. In this observational study, we examined whether treatment of hypertension modulates adverse effects of WPP in ischemic stroke. We have chosen to define WPP as a value of ≥70 mmHg as this cut point has been shown to be associated with poorer outcomes in previous studies [7] . International Journal of Clinical Medicine
Methods

Study Design and Patient/Variable Selection
Retrospective chart review was performed and follow-up outcomes (49.7 ± 22.4 months) were ascertained in 343 consecutive patients treated for AIS at a single tertiary care academic medical center, certified as Primary Stroke Center [24] . Patients were identified utilizing a hospital billing database, according to the discharge diagnosis code (ICD9 for acute stroke-434.xx, 435.xx, or 436.xx-in addition patients needed to have had an echocardiogram that was ordered to look for an embolic source).
The hospital's diagnostic evaluation and therapeutic interventions followed the 2003 "Guideline for The Management of Patients with Ischemic Stroke" [25] .
Quality of care was ascertained according to the "Get With The Guidelines" [26] program criteria. During the study time period (2008 to 2011), the treating hospital was recognized for the performance achievement, with more than 85% of patients having received care according to the guideline, attesting to the quality and consistency of the care provided. Initial BP measurements were performed by properly trained Emergency Department triage RN in the supine patient, employing automated BP measurement unit with an appropriate size cuff for the patient's habitus. The discharge criterion for hypertension management was attaining BP of <140/90 mmHg, unless it could not be tolerated; this is consistent with the current "Evidence-Based Guideline for the Management of High BP in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)" [27] .
The choice of employed anti-hypertensive medications was determined by patient co-morbidities and the intensity of each required therapy. Treatment followed recommendation of "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure" [28] . All medications were titrated to the maximal safe dosing to ensure goal BP management.
Outcomes were assessed until 2015 and were classified as in-hospital mortality in patients who expired during index admission, follow-up mortality in patients who expired during the follow-up period, and survivors. Outcomes and causes of death were determined through hospital charts and death certificates, and status was verified through the Social Security Death Index database [29] [30] . The study was approved by the institutional IRB at the Albany Medical College.
Statistical Analysis
Continuous variables were expressed as means and standard deviations. Differences in continuous variables were assessed with an unpaired t-test and non-parametric Kruskall-Wallis test, when appropriate. Categorical data was expressed as proportions and the differences in proportions were assessed with Chi-square analysis and Fisher's exact test, when appropriate. 
Results
After inclusion and exclusion criteria were applied a total of 322 patients were identified for the study cohort ( Table 1 ). The population was 43.8% female and the average age was 66.5 years. Table 1 Regarding the choice of antihypertensive class-ACEI/ARB or BB-patients in either of these two classes were similar in baseline comorbidity profile except for having a history of coronary artery disease without prior revascularization, which was more common in BB group (Table 2) .
Outcomes
Overall in-hospital mortality was 5.3%. The average length of follow-up data was 49.7 months. Mortality during follow up for the overall cohort was 28.2% (Table 1) . There was no difference between PP groups for in-hospital mortality.
Follow-up mortality was significantly higher among those with a baseline PP > 70 (37.4 vs. 23.2%, p = 0.009) ( Table 1) . On univariate analysis, older age, the International Journal of Clinical Medicine presence of CAD without prior revascularization, presence of PAD, having a creatinine > 2 mg/dl or being on hemodialysis, having a Glasgow Coma Scale score > 9, PP > 70, requiring intravenous anti-hypertensive therapy during the hospitalization, and being on a BB based anti-hypertensive regimen were all significantly associated with increased follow-up mortality. In-hospital mortality was non-significantly lower for patients treated with ACEI/ARB compared to those not treated with ACEI/ARB (3.7% vs. 8.6%); follow up mortality was similar between the anti-hypertensive therapy groups (27.4% vs. 24.2%, p = 0.150).
Looking at various combinations of ACEI/ARB and BB based therapy, being on an ACEI/ARB based therapy without BB was associated with lowest in-hospital and follow up mortality (2.5% and 16%, respectively, p = 0.003) ( Table 3) .
After adjustment for covariates in multivariate analysis (Table 4) Abbreviations: CAD-coronary artery disease; HTN-hypertension; Rx -therapy; IV-intravenous; ACEI-angiotensin converting enzyme inhibitor; ARB-angiotensin receptor blockers. International Journal of Clinical Medicine (Table 4) . Among patients with PP < 70, being on an ACEI/ARB based therapy without a BB was associated with a significantly lower follow-up mortality (OR 0.07, 95% confidence interval 0.01 -0.477, p = 0.0066).
Discussion
In this retrospective cohort of patients admitted with a diagnosis of AIS, PP was not independently associated with short or long term mortality, but the use of an ACEI or ARB based antihypertensive regimen was associated with lower in-hospital among patients with PP <70 or ≥70. ACEI/ARB without BB was associated with lower follow-up mortality only those patients with baseline PP < 70.
A widened PP has been demonstrated in multiple analyses to be associated Neuroprotection International Trial; however, as with the current analysis, the baseline PP was not associated with follow-up outcomes after adjusting for comorbidities [7] . The association of average PP over the course of hospitalization with outcomes deserves further evaluation.
In contrast, choice of antihypertensive therapy remained significantly associated with outcomes with some notable differences based on baseline PP categorization. Regardless of baseline PP, being on an ACEI/ARB based antihypertensive therapy is associated with favorable in-hospital outcomes during AIS and including BB into the regimen attenuates the benefit. For long term mortality outcomes, ACEI/ARB based therapy was found to be beneficial in patients with PP < 70, with attenuation, again, from addition of BB. There was a reduction in mortality with ACEI/ARB based therapy, without BB, among patients with PP ≥ 70 however it did not meet statistical significance (OR 0.363, p = 0.054).
The Scandinavian Candesartan Acute Stroke Trial (SCAST) randomized patients with acute stroke (the majority of whom, ~85%, had AIS) to initial treatment with Candesartan or placebo for hypertension management. This was not a BP target study and no data on PP was provided. The investigators found no significant difference in the primary outcome at 6 months or 3 years [33] . A direct comparison between a randomized study and a retrospective study is not possible however the current analysis may suggest that PP may be an important consideration when analyzing the effect of antihypertensive therapy on AIS outcomes.
BB, on the other hand, were not associated with improved short and long term outcomes and attenuated some of the benefit seen with ACEI/ARB therapy.
BB has been relegated to second line therapy in hypertension in general [27] . In regards to AIS, most of the data on BB therapy has been derived from retrospective studies. A recent analysis by Koton and colleagues looked at pre-stroke use of BB for hypertension management and post stroke outcomes [34] . These investigators found no effect on outcomes (stroke severity, recurrent stroke, or mortality) with the use of BB for pre-stroke hypertension therapy. Phelan and colleagues found a decrease in the in-hospital mortality in patients with AIS who had their home BB therapy continued during the first 3 days of AIS versus patients in whom BB therapy was discontinued [35] . This was despite a higher comorbid profile among patients on BB therapy [35] . Similarly, Tziomalos found worse in-hospital outcomes in patients treated with BB prior to AIS, than in those not treated with BB [36] . In contrast to our findings, Tziomalos and colleagues did not find a beneficial effect of ACEI or ARB therapy [36] . Similarly, Sykora and colleagues found improved in-hospital and 3-month AIS outcomes with the use of BB pre-stroke [37] . One important distinction from the current analysis is the duration of follow up; in our study, the duration of follow-up was significantly longer. In addition, distinctions in patient populations by PP have International Journal of Clinical Medicine not been previously reported. Given the disparate findings among data sets, a well-designed randomized controlled trial examining the role of BB therapy in improving post stroke outcomes may be warranted.
Several important limitations of the current analysis need to be acknowledged.
The choice of antihypertensive therapy was left to the discretion of the provider and thus introduces indication bias that cannot be adequately addressed in the current format. In addition, there is no means to know how patients were treated after the point of discharge. Addition or subtraction of hypertensive medications may have led to muted effects seen in the various subgroup analyses. Finally, our study contained modest sample size and follow up period as a larger sample size with longer follow up would be beneficial in studying this matter.
Conclusion
Despite these limitations, the current analysis revealed important distinctions within patients who have suffered AIS. ACEI/ARB based antihypertensive management appears to provide the most favorable short and long term outcomes in patients with AIS. This seems to be most prominent among patients with AIS and PP < 70 at presentation. Future randomized controlled trials of patients with AIS should look at antihypertensive classes and PP interactions.
